# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2020

# **CHF Solutions, Inc.**

(Exact Name of Registrant as Specified in its Charter)

001-35312

No. 68-0533453

Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)			
	lley View Road, Eden Prairie, MN of Principal Executive Offices) (Zi				
(Registrant	(952) 345-4200 's Telephone Number, Including A	rea Code)			
Securities registered pursuant to <u>Section 12(b)</u> of the Act:					
Title of each class Common Stock, par value \$0.0001 per share	Trading Symbol(s) CHFS	Name of each exchange on which registered Nasdaq Capital Market			
Check the appropriate box below if the Form 8-1 under any of the following provisions:	K filing is intended to simultaneous	y satisfy the filing obligation of the registrant			
☐ Written communications pursuant to Rule 425 ur	nder the Securities Act (17 CFR 230.425)				

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Emerging growth company  $\square$ 

**Delaware** 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

## Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) At the annual meeting of stockholders (the "Annual Meeting") of CHF Solutions, Inc. (the "Company") held on May 20, 2020, the following proposals were brought before the meeting (i) the election of two Class I director nominees to the Company's board of directors to serve three-year terms ("Proposal 1"), (ii) the approval, on an advisory basis, of Baker Tilly Virchow Krause, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020 ("Proposal 2"), (iii) the approval of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company's outstanding common stock at a ratio in the range of 1-for-5 to 1-for-30, to be determined at the discretion of the Company's Board of Directors, whereby each outstanding 5 to 30 shares would be combined, converted and changed into 1 share of Company common stock, without reducing the number of authorized shares of Company common stock ("Proposal 3") and (iv) the authorization for one or more adjournments of the annual meeting to solicit additional proxies in the event there were insufficient votes to approve Proposal 3 ("Proposal 4").

For Proposal 1, the two nominees receiving the highest number of "FOR" votes at the annual meeting were elected as directors. Proposal 2 and Proposal 4 required the affirmative vote of the holders of a majority of shares entitled to vote and present at the Annual Meeting. Proposal 3 required an affirmative vote of holders of a majority of the shares entitled to vote at the annual meeting. The proposals are described in detail in the Company's definitive proxy statement filed on April 13, 2020 with the Securities and Exchange Commission.

A total of 22,327,413 shares of the Company's common stock were present at the meeting in person or by proxy, which represents approximately 68.49% of the shares of common stock outstanding as of the record date for the Annual Meeting.

(b) The results of the voting are shown below.

## **Proposal 1—Election of Directors**

DIRECTOR NOMINEES	VOTES FOR	WITHHELD	BROKER NON-VOTES
Steve Brandt	7,013,511	1,399,656	13,914,246
Warren S. Watson	6.982.874	1,430,293	13.914.246

# Proposal 2—Advisory Approval of Independent Registered Public Accounting Firm for the year ending December 31, 2020

			BROKER
VOTES FOR	VOTES AGAINST	ABSTAIN	NON-VOTES
19,144,376	2,374,727	808,310	N/A

Proposal 4— Authorization of one or more adjournments of the annual meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 3

			BROKER
VOTES FOR	VOTES AGAINST	ABSTAIN	NON-VOTES
14,129,410	8,115,075	82,928	0

#### Item 8.01 Other Events.

At the time of the Annual Meeting, there were insufficient votes to pass Proposal 3, which sought to approve an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of its outstanding common stock at a ratio in the range of 1-for-5 to 1-for-30, to be determined at the discretion of the Company's Board of Directors, whereby each outstanding 5 to 30 shares would be combined, converted and changed into 1 share of Company common stock, without reducing the number of authorized shares of Company common stock. In accordance with the authority granted pursuant to the approval of Proposal 4, the Annual Meeting was adjourned. As announced at the Annual Meeting, such meeting will reconvene at 2:00 p.m. US Central Time on June 19, 2020 virtually at <a href="https://web.lumiagm.com/257409059">https://web.lumiagm.com/257409059</a>. During the period of adjournment, the Company will continue to accept stockholder votes on Proposal 3.

A copy of the press release issued by the Company with respect to the annual meeting is attached hereto as Exhibit 99.1.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 CHF Solutions, Inc. Press Release, dated May 22, 2020

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 22, 2020 CHF SOLUTIONS, INC.

By: /S/ CLAUDIA DRAYTON

Name: Claudia Drayton

Title: Chief Financial Officer



CHF Solutions, Inc. Announces Adjournment of Annual Meeting of Stockholders

## Scheduled to Reconvene June 19, 2020

# Company Strongly Encourages Stockholders to Vote

EDEN PRAIRIE, MN, May 22, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) ("CHF Solutions") today announced that its 2020 Annual Meeting of Stockholders held on May 20, 2020 convened and then adjourned until June 19, 2020 2:00 p.m. US Central Time at <a href="https://web.lumiagm.com/257409059">https://web.lumiagm.com/257409059</a> to solicit additional proxies for Proposal 3, granting the Board of Directors the discretion to implement a reverse stock split ("Proposal 3").

The Board of Directors believes approval of Proposal 3 is in the best interests of CHF Solutions and its stockholders because a reverse stock split may be necessary to maintain the listing of CHF Solutions' common stock on the NASDAQ Capital Market ("Nasdaq"). A delisting of the common stock from Nasdaq could significantly impair CHF Solutions' ability to raise additional capital, which may be needed to operate its business; it could result in lower prices for its common stock and larger spreads in the bid and ask prices for the common stock; and it could impact a stockholders ability to trade shares of common stock. Proposal 3 is described in more detail in the company's proxy statement, dated April 13, 2020 (the "Proxy Statement"), furnished to stockholders in connection with the 2020 Annual Meeting. As stated in the Proxy Statement, CHF Solutions only intends to implement the reverse stock split if needed to maintain its listing on Nasdaq.

Stockholders have thus far strongly supported Proposal 3. At the time of the meeting, approximately 56% of the shares that had been voted on Proposal 3 had been voted in its favor. However, the favorable votes were less than the absolute majority of all outstanding shares needed for approval. Proposals 1, 2 and 4 were approved at the Annual Meeting.

CHF Solutions encourages any stockholder that has not yet voted its shares or is uncertain if their shares have been voted to contact their broker or bank. The Board of Directors and management respectfully requests stockholders as of the record date, April 6, 2020, to please vote their proxies as soon as possible, but no later than June 18, 2020 at 11:59 p.m. (Eastern Time). Stockholders who have previously submitted their proxy or otherwise voted for the annual meeting and who do not want to change their vote need not take any action. For questions relating to the voting of shares or to request additional or misplaced proxy voting materials, please contact the Company at <u>ir@chf-solutions.com</u>.

As described in the proxy statement, a stockholder may use one of the following simple methods to vote with respect to Proposal 3:

- Vote by Internet: Go to the website <u>www.voteproxy.com</u> and follow the on-screen instructions or scan the QR code with a smartphone. The stockholder should have their proxy card available when they access the page.
- Vote by Telephone: Please call the toll-free number listed on the stockholder's proxy card or voting instruction form and follow the instructions provided.
- Vote by Mail: Mark, sign, date and return the stockholder's proxy card or voting instruction form and return it in the envelope provided as soon as possible.

Votes must be received by 11:59 P.M. Eastern Time on June 18, 2020 to be counted. After this time, the only way to cast a vote is at the adjourned Annual Meeting on June 19, 2020, 2:00 p.m. US Central Time at <a href="https://web.lumiagm.com/257409059">https://web.lumiagm.com/257409059</a>.

# YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

#### **About CHF Solutions**

CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the Lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow<sup>TM</sup> system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

# About the Aquadex SmartFlow System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

# **Forward-Looking Statements**

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the company's need to raise additional capital, the effect of stockholders not approving Proposal 3 and the impact of delisting of the company's common stock. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

## **Important Information**

In connection with the solicitation of proxies, on April 13, 2020, CHF Solutions, Inc. filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") in connection with the company's 2020 Annual Meeting. STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE DEFINITIVE PROXY MATERIALS AND ANY OTHER RELEVANT SOLICITATION MATERIALS FILED BY CHF SOLUTIONS, INC. WITH THE SEC BEFORE MAKING ANY VOTING OR INVESTMENT DECISION BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION. The company's proxy statement and any other materials filed by the company with the SEC can be obtained free of charge at the SEC's web site at <a href="https://www.sec.gov.">www.sec.gov.</a>. The company's proxy statement, notice of annual meeting, and annual report to shareholders are available free of charge on the company's Investor Relations website at <a href="https://www.chfsolutions.com">www.chfsolutions.com</a>. All stockholders may also write to the company at the following address to request copies of these materials: CHF Solutions, Inc. 12988 Valley View Road, Eden Prairie, Minnesota 55344 Attention: Corporate Secretary. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement.

# **CONTACTS**

## **INVESTORS:**

Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com

# **MEDIA:**

Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com

###